Ying Han¹, Lingying Wu², Shumin Li²

¹ Department of Gynecologic Oncology, Peking union   Medical College;Department of Gynecologic Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, ²Department of Gynecologic Oncology, Peking union   Medical College

Objective:To observe the therapeutic effect of Bevacizumab (BEV) combined chemotherapy to treat persistent and/or recurrent uterine sarcomas. Method: From May 2006 to May 2014 clinical data from 4 persistent and/or recurrent uterine sarcoma patients who accepted BEV combined chemotherapy in our hospital was retrospectively analyzed. This data was used to evaluate the response rate (complete response+ partial response), progression-free survival time(PFS), overall survival time(OS), and the safety and toxicity reaction. Result: Of four patients, 1 case achieved complete response (CR), disease-free survival time is 96 months; 1 case to partial response (PR), PFS is 13 months, OS is 25 months; 1 case to stable disease (SD), PFS is 9 months, OS is 24 months; 1 case to progressive disease (PD), PFS is 3 months and OS is 9 months. Treatment related adverse reactions included bone marrow suppression and gastrointestinal reaction. One Patient exhibited IV grade bone marrow suppression (thrombocytopenia), the other three were diagnosed with II grade bone marrow suppression (leukopenia). Half of the cases had II grade gastrointestinal reactions, and the other two had I grade gastrointestinal reactions. Conclusion: BEV combined chemotherapy could effectively control the persistent and/or recurrent uterine sarcoma, is well tolerated, and can possible be used as a safe and effective candidate therapy for persistent and/or recurrent uterine sarcomas.

Key Words: Uterine sarcomas, Bevacizumab, Combined chemotherapy